Table 4 Multivariate analysis of the OS and the BCSS in Cohort 1

Age at diagnosis

20–30

Ref

Ref

31–40

0.876

0.672–1.141

0.326

0.982

0.736–1.309

0.899

41–50

0.699

0.542–0.903

0.006

0.748

0.566–0.989

0.041

51–60

0.946

0.735–1.217

0.665

0.920

0.698–1.212

0.553

61–70

1.343

1.045–1.726

0.021

0.942

0.714–1.243

0.674

71–80

3.008

2.341–3.865

 < 0.001

1.498

1.133–1.979

0.004

Race

White

Ref

Ref

Black

1.600

1.505–1.701

 < 0.001

1.544

1.423–1.674

 < 0.001

Others

0.843

0.787–0.903

 < 0.001

0.889

0.809–1.976

0.014

Histological grade

1

Ref

Ref

2

1.172

1.102–1.246

 < 0.001

1.630

1.451–1.832

 < 0.001

3

1.540

1.439–1.648

 < 0.001

2.682

2.377–3.025

 < 0.001

T stage

1

Ref

Ref

2

1.606

1.476–1.747

 < 0.001

1.697

1.521–1.894

 < 0.001

3

2.155

1.929–2.407

 < 0.001

2.559

2.229–2.938

 < 0.001

4

3.614

3.159–4.135

 < 0.001

4.497

3.831–5.279

 < 0.001

N stage

0

Ref

Ref

1

1.413

1.319–1.514

 < 0.001

1.679

1.534–1.838

 < 0.001

2

1.974

1.730–2.252

 < 0.001

2.550

2.179–2.984

 < 0.001

3

2.867

2.514–3.369

 < 0.001

3.870

3.315–4.517

 < 0.001

HER-2

Negative

-

Ref

Positive

-

-

-

0.599

0.553–0.650

 < 0.001

Stage

I

Ref

Ref

II

1.005

0.910–1.109

0.925

1.574

1.368–1.811

 < 0.001

III

1.163

0.987–1.370

0.072

1.928

1.564–2.377

 < 0.001

HR status

ER + /PR + 

Ref

Ref

ER + /PR-

1.247

1.173–1.325

 < 0.001

1.686

1.550–1.834

 < 0.001

ER-/PR + 

1.567

1.321–1.858

 < 0.001

2.090

1.696–2.574

 < 0.001

ER-/PR-

1.501

1.417–1.589

 < 0.001

2.019

1.872–2.178

 < 0.001